Ossianix Cracks Open The Blood-Brain Barrier
Executive Summary
By using the binding region of shark antibodies as a carrier to cross the blood-brain barrier, Ossianix reckons it has made significant progress against an issue that has held back the development of CNS-active neurological therapies.
You may also be interested in...
AdAlta CEO On Shark Antibody Technology
AdAlta CEO Sam Cobb discusses development of the company's novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.
Lundbeck funds propel Ossianix towards Series A in 2013
A strategic investment from CNS specialist H. Lundbeck A/S will allow Ossianix to undertake preclinical proof-of-concept studies that, in turn, could permit the Philadelphia-based start-up to raise further money in a Series A round sometime in 2013, according to CEO Frank Walsh.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.